search
Back to results

Fetal Cell Receptors Repertoire (MoreCCR)

Primary Purpose

Venous Ulcer, Sickle Cell Ulcer, Diabetic Ulcer

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Saliva sampling
Blood sampling
Interviews
Clinical examination
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Venous Ulcer focused on measuring Microchimerism, Foetal stem cells, Receptors

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Common criteria : Adult women, Post-partum: having been pregnant for any length of time, Having signed a free and informed consent form, Primiparous or multiparous, Affiliated to a health insurance Patients : - Patients with venous ulcers, diabetes or sickle cell disease, Control group patients : Volunteers, Age-matched, Without skin ulcers. There are no specific criteria for children. Exclusion Criteria: Minors (for patients) Under court protection, curatorship, guardianship (for patients) Immunocompromised patients for any reason whatsoever Refusal of consent Refusal of blood and/or saliva samples for themselves or a member of their family

Sites / Locations

  • Dermatology unit - Cochin Hospital - APHP

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Patients

Patient "Controls group "

Children

Arm Description

Patients who have had at least one pregnancy and have a venous ulcer, diabetic ulcer or sickle cell ulcer

Post-partum women of the same age but without wounds.

Outcomes

Primary Outcome Measures

Transcriptomic analysis by single cell sequencing
Transcriptomic analysis by single cell RNA sequencing (Smart-seq3 protocol) of fetal cells sorted from peripheral blood

Secondary Outcome Measures

Full Information

First Posted
September 4, 2023
Last Updated
September 18, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT06031714
Brief Title
Fetal Cell Receptors Repertoire
Acronym
MoreCCR
Official Title
"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial"
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
April 1, 2026 (Anticipated)
Study Completion Date
November 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.
Detailed Description
The aim of regenerative medicine is to repair damaged tissue using different sources of autologous or heterologous stem cells. These cells are then cultured to achieve amplification and differentiation adapted to the cell type of the organ to be repaired. These methods are potentially effective, but involve risks and limitations, in particular the risks of genetic modifications during culture or contamination by residual ES or iPS cells. Immunosuppressive treatment is also necessary if the source of stem cells is allogeneic. Finally, implantation of this type of culture may also be unsuccessful. Our team is seeking for an alternative strategy to these methods. This relies on the presence of a niche of foetal cells transferred during pregnancy that persist after delivery. In fact, all mammalian pregnancies lead to foetal-maternal cell transfer. The foetal cells -transferred to the maternal circulation- contain different types of stem cells that will remain in the maternal bone marrow and persist there for the rest of the mother's life. The team has shown that in the event of cutaneous wounds in post-gestational mice, a population of CD11b+ CD34+ CD31+ foetal progenitors was recruited from the maternal bone marrow to the cutaneous granulation tissue. These cells over-express the chemokine receptor CCR2 compared with their adult counterparts. Consequently, the injection of low, so-called physiological, doses of the CCL2 chemokine subcutaneously into wounds accelerates normal wound healing and restores delayed healing in two pathological models. This pro-healing activity is linked to the specific recruitment of foetal stem cells to the site of injected wounds. These low doses of CCL2 never affected wound healing in virgin mice, confirming that this type of treatment does not alter the homeostasis of adult cells. The therapeutic strategy the investigators are proposing, entitled "natural stem therapy", is based on this reservoir of foetal stem cells present in every woman who has had at least one pregnancy, i.e. more than 60% of adult women in western countries. In order to test the validity of this concept, it is important to ascertain the pathways by which foetal cells are chemoattracted in the human species, in particular the CCR2/CCL2 pathway.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Ulcer, Sickle Cell Ulcer, Diabetic Ulcer, Post-partum Women
Keywords
Microchimerism, Foetal stem cells, Receptors

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients
Arm Type
Other
Arm Description
Patients who have had at least one pregnancy and have a venous ulcer, diabetic ulcer or sickle cell ulcer
Arm Title
Patient "Controls group "
Arm Type
Other
Arm Description
Post-partum women of the same age but without wounds.
Arm Title
Children
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
Saliva sampling
Intervention Description
HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
Intervention Type
Other
Intervention Name(s)
Blood sampling
Intervention Description
Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells, The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.
Intervention Type
Other
Intervention Name(s)
Interviews
Intervention Description
V2 and/or V3
Intervention Type
Other
Intervention Name(s)
Clinical examination
Intervention Description
V2 and/or V3
Primary Outcome Measure Information:
Title
Transcriptomic analysis by single cell sequencing
Description
Transcriptomic analysis by single cell RNA sequencing (Smart-seq3 protocol) of fetal cells sorted from peripheral blood
Time Frame
Month 1 up to month 5

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Common criteria : Adult women, Post-partum: having been pregnant for any length of time, Having signed a free and informed consent form, Primiparous or multiparous, Affiliated to a health insurance Patients : - Patients with venous ulcers, diabetes or sickle cell disease, Control group patients : Volunteers, Age-matched, Without skin ulcers. There are no specific criteria for children. Exclusion Criteria: Minors (for patients) Under court protection, curatorship, guardianship (for patients) Immunocompromised patients for any reason whatsoever Refusal of consent Refusal of blood and/or saliva samples for themselves or a member of their family
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sélim ARACTINGI, MD, PHD
Phone
00 33 1 58 41 18 13
Email
selim.aractingi@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Marie Benhammani-Godard
Phone
00 33 1 58 41 11 90
Email
marie.godard@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sélim ARACTINGI, MD, PHD
Organizational Affiliation
Dermatology unit, Cochin Hospital - APHP
Official's Role
Study Director
Facility Information:
Facility Name
Dermatology unit - Cochin Hospital - APHP
City
Paris
State/Province
Ile De France
ZIP/Postal Code
75014
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sélim ARACTINGI, MD, PhD
Phone
0033 1 58 41 18 13
Email
selim.aractingi@aphp.fr
First Name & Middle Initial & Last Name & Degree
Bénédicte OULES, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Fetal Cell Receptors Repertoire

We'll reach out to this number within 24 hrs